Evidence map›Paper›PMID 29419930›Full record

ArticleMolecular oncology2018

STAT1 is a sex-specific tumor suppressor in colitis-associated colorectal cancer.

Ilija Crnčec, Madhura Modak, Claire Gordziel, Jasmin Svinka, Irene Scharf, Stefan Moritsch, Paulina Pathria, Michaela Schlederer, Lukas Kenner, Gerald Timelthaler and 8 more

Open access · goldAbstract read
In one paragraph

Article in Molecular oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
1.5field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Colitis Induces Sex-Specific Intestinal Transcriptomic Responses in Mice.International journal of molecular sciences · 2022
    Article
  10. STAT1-mediated induction of Ly6c-expressing macrophages are involved in the pathogenesis of an acute colitis model.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 2 countries.

Ilija CrnčecInstitute of Cancer Research, Medical University Vienna & Comprehensive Cancer Center (CCC), Vienna, Austria.
Madhura ModakInstitute of Immunology, Medical University Vienna, Austria.
Claire GordzielInstitute of Biochemistry II, University Hospital Jena, Germany.
Jasmin SvinkaInstitute of Cancer Research, Medical University Vienna & Comprehensive Cancer Center (CCC), Vienna, Austria.
Irene ScharfInstitute of Cancer Research, Medical University Vienna & Comprehensive Cancer Center (CCC), Vienna, Austria.
Stefan MoritschInstitute of Cancer Research, Medical University Vienna & Comprehensive Cancer Center (CCC), Vienna, Austria.
Paulina PathriaInstitute of Cancer Research, Medical University Vienna & Comprehensive Cancer Center (CCC), Vienna, Austria.
Michaela SchledererLudwig Boltzmann Institute for Cancer Research LBICR, Vienna, Austria.
Lukas KennerLudwig Boltzmann Institute for Cancer Research LBICR, Vienna, Austria.
Gerald TimelthalerInstitute of Cancer Research, Medical University Vienna & Comprehensive Cancer Center (CCC), Vienna, Austria.
Mathias MüllerInstitute of Animal Breeding and Genetics and Biomodels Austria, University of Veterinary Medicine Vienna, Austria.
Birgit StroblInstitute of Animal Breeding and Genetics and Biomodels Austria, University of Veterinary Medicine Vienna, Austria.
Emilio CasanovaLudwig Boltzmann Institute for Cancer Research LBICR, Vienna, Austria.
Editha BayerInstitute of Cancer Research, Medical University Vienna & Comprehensive Cancer Center (CCC), Vienna, Austria.
Thomas MohrInstitute of Cancer Research, Medical University Vienna & Comprehensive Cancer Center (CCC), Vienna, Austria.
Johannes StöcklInstitute of Immunology, Medical University Vienna, Austria.
Karlheinz FriedrichInstitute of Biochemistry II, University Hospital Jena, Germany.
Robert EferlInstitute of Cancer Research, Medical University Vienna & Comprehensive Cancer Center (CCC), Vienna, Austria.ORCID 0000-0002-6074-7144
Comprehensive Cancer Center Vienna · ATUniversity of Veterinary Medicine Vienna · ATJena University Hospital · DEMedical University of Vienna · ATLudwig Boltzmann Institute for Cancer Research · AT

Funding

Austrian Science Fund FWF P 25925Austrian Science Fund FWF P 26908Austrian Science Fund FWF P 29222
6 · The paper itself

Abstract

The interferon-inducible transcription factor STAT1 is a tumor suppressor in various malignancies. We investigated sex-specific STAT1 functions in colitis and colitis-associated colorectal cancer (CRC) using mice with specific STAT1 deletion in intestinal epithelial cells (STAT1

Indexed as

Sex CharacteristicsAnimalsCD8-Positive T-LymphocytesChemokinesColitisColorectal NeoplasmsDextran SulfateFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMice, TransgenicReceptors, Antigen, T-Cell, alpha-betaSTAT1 Transcription FactorTumor Suppressor ProteinsChemokinesDextran SulfateReceptors, Antigen, T-Cell, alpha-betaSTAT1 protein, humanStat1 protein, mouseSTAT1 Transcription FactorTumor Suppressor ProteinsCD8+ T cellscolitiscolorectal cancergendersexSTAT1

Identifiers

PMID29419930
PMCPMC5891040
OpenAlexW2789769227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.